PO.MCB07.02 · 分子与细胞生物学
一种SWI/SNF特异性的Ig样结构域SWIFT是转录因子结合枢纽
A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding hub
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
哺乳动物SWI/SNF(BAF)染色质重塑复合物调控DNA可及性和基因表达,然而其在染色质上被靶向定位的机制仍未被完全阐明。我们在此将SWIFT(SWI/SNF Ig-Fold for Transcription Factor Interactions,用于转录因子相互作用的SWI/SNF Ig折叠)定义为一个进化上保守的通用转录因子(TF)结合平台,其位于mSWI/SNF核心模块内SMARCD家族亚基上。SWIFT对于在体外和细胞中与谱系特异性TF(PU.1)的转录激活结构域直接相互作用是必需且充分的,SWIFT中的单个氨基酸突变即可破坏PU.1-mSWI/SNF结合,抑制位点特异性的复合物靶向和活性,并减弱PU.1依赖性急性髓系白血病(AML)癌细胞的致癌基因表达和增殖。
此外,单独显性表达SWIFT结构域可将TF从mSWI/SNF复合物中隔离,并跨不同谱系“毒害”TF成瘾的癌细胞。最后,我们揭示了谱系特异性TF对特定SMARCD亚基旁系同源物的SWIFT结构域具有显著的偏好性。这些TF对SMARCD旁系同源物的特异性亲和力与它们在人类细胞和组织中的组织特异性及分化状态特异性表达模式相一致,提示mSWI/SNF亚基组成的转换可微调对TF的亲和力,而这些TF在正常分化和肿瘤发生过程中主导着特化的细胞状态转变。总之,这项工作揭示了一个新的mSWI/SNF生化界面,可用于在多种转录成瘾癌症中进行靶向治疗调控。
查看英文原文 English abstract
Mammalian SWI/SNF (BAF) chromatin remodeling complexes modulate DNA accessibility and gene expression, however, the mechanisms by which they are targeted on chromatin remain incompletely understood. Here, we define SWIFT ( SW I/SNF I g-Fold for T ranscription F actor Interactions), found on the SMARCD family of subunits within the mSWI/SNF core module as an evolutionarily conserved, universal transcription factor (TF) binding platform. SWIFT is necessary and sufficient for direct interaction with the transactivation domain of a lineage-specific TF, PU.1, in vitro and in cells, with a single amino acid mutation in SWIFT able to disrupt PU.1-mSWI/SNF binding, inhibit site-specific complex targeting and activity, and attenuate oncogenic gene expression and proliferation of PU.1-dependent acute myeloid leukemia (AML) cancer cells.
Further, dominant expression of the SWIFT domain in isolation sequesters TFs from mSWI/SNF complexes and “poisons” TF-addicted cancer cells across different lineages. Finally, we uncover striking preferences of lineage-specific TFs for the SWIFT domains of specific SMARCD subunit paralogs. These SMARCD paralog-specific affinities of TFs align with their tissue- and differentiation state-specific expression patterns across human cells and tissues, suggesting that that switches in mSWI/SNF subunit composition fine-tune affinities for TFs that govern specialized cell state transitions during normal differentiation and tumorigenesis.In conclusion, this work unmasks a novel mSWI/SNF biochemical interface amenable to targeted therapeutic modulation in a diverse collection of transcriptionally addicted cancers.
利益披露 Disclosure
S. U. Jain, None.
K. E. Williamson,
Flare Therapeutics Employment.
A. Ying, None..
A. M. Turner, None.
J. R. Jiang,
Entrada Therapeutics Employment.
S. Raval, None..
K. So, None..
M. J. Allison, None..
A. Sankar, None..
D. Guerra, None..
N. Mashtalir, None..
H. H. Rohrs, None..
C. F. Lichti, None..
M. Papanastasiou, None..
J. A. Paulo, None..
S. Gygi, None..
M. L. Gross, None.
C. Kadoch,
Foghorn Therapeutics Scientific Founder, Scientific Advisor to the Board of Directors, Scientific Advisory Board member, shareholder, and consultant for Foghorn Therapeutics, Inc. (Cambridge, MA).
Nereid Therapeutics Scientific Advisory Board.